Scott S. Tykodi, MD of Seattle Cancer Care Alliance discusses the recently released Checkmate 214 data and how favorable RCC…
Browsing: Acute Lymphoblastic Leukemia
Michael N. Needle, MD, and Chief Medical Officer of AVEO Oncology goes over the TIVO-1 Trial results first released in…
Dr. Scott S. Tykodi, MD reveals the results of the Checkmate – 214 trial with combined immunotherapy nivolumab plus ipilimumab…
Michael Needle, MD and Chief Medical Officer of AVEO Oncology goes over why and how Tivozanib (FOTIVDA(R)) was given approval…
K. Robert Shen, MD of of the Mayo Clinic in Rochester, MN discusses what to do with an esophageal cancer…
Patients often struggle with the decision to seek an opinion elsewhere. Is your own doctors opinion enough? Will you offend…
Dr. Jack West reviews the important, clinically relevant results of the CheckMate-153 trial that asks whether there is a value…
Dr. Jack West summarizes the likely practice-changing results of the FLAURA trial of osimertinib vs. standard of care EGFR TKI…
Dr. Jack West reviews data from ESMO 2017 & the NEJM paper on the PACIFIC trial of durvalumab vs. placebo…
In this presentation from the 2017 Great Debates & Updates in GI Malignancies, Dr. David H. Ilson argues that peri-operative…
In this presentation from the 2017 Great Debates & Updates in GI Malignancies, Dr. Jonathan Strosberg argues that there is…
In this presentation from the 2017 Great Debates & Updates in GI Malignancies, Dr. Michael A. Choti argues that there…
In this presentation from the 2017 Great Debates & Updates in GI Malignancies, Dr. Zsofia K. Stadler assesses the state…
In this presentation from the 2017 Great Debates & Updates in GI Malignancies, Dr. Scott Kopetz provides an update on…
In this presentation from the 2017 Great Debates & Updates in GI Malignancies, Dr. Tanios S. Bekaii-Saab argues that the…
In this presentation from the 2017 Great Debates & Updates in GI Malignancies, Dr. Neil H. Segal provides an update…
In this presentation from the 2017 Great Debates & Updates in GI Malignancies, Dr. Zsofia K. Stadler provides an update…
Dr. Jack West explains the potential value PD-L1 expression during the initial workup of patients with advanced NSCLC, in the…
Held on 29 June 2017 in Barcelona, Spain, the Optimizing the Continuum of Care for Patients with Pancreatic Cancer symposium…
Dr. Jack West reviews data from pivotal trials showing that platforms that enable better communication between the cancer patient and…
K. Robert Shen, MD, of the Mayo Clinic in Rochester, MN discusses how a new study highlights how estrogen could…
Professor Gareth Thomas at the University of Southampton, United Kingdom discusses the next steps for the preclinical models of GKT831
Hagop M. Kantarjian, MD of MD Anderson Cancer Center goes over some possible next steps for Inotuzumab after it has…
Hagop M. Kantarjian, MD of MD Anderson Cancer Center discusses how veno occlusive disease may cause complications while using inotuzumab…
Hagop M. Kantarjian, MD of MD Anderson Cancer Center states “We are witnessing a slow motion revolution in ALL” talking…
Professor Gareth Thomas at the University of Southampton, United Kingdom discusses the relatively well tolerated GKT831 in other disease states.
K. Robert Shen, MD of Mayo Clinic in Rochester reports that female patients with locally advanced esophageal cancer that is…
Hagop M. Kantarjian, MD of MD Anderson Cancer Center’s Department of Leukemia says now that Besponsa or Inotuzumab is FDA…
Professor Gareth Thomas at the University of Southampton, United Kingdom discusses his preclinical research about cancer associated fibroblasts (CAFs) and…
Hagop M. Kantarjian, MD of MD Anderson Cancer Center’s Department of Leukemia states the median survival rate nearly doubles combining…
Professor Gareth Thomas of University of Southampton discusses data in multiple preclinical models that showed GKT831 efficiently targeted cancer associated…
Dr. Jack West reviews the promise of combinations of immunotherapies for advanced NSCLC and the implications for the field of…
Dr. Jack West discusses the implications of a positive FLAURA trial, which revealed a significant improvement in progression-free survival for…
Dr. Jack West reviews the potential new role for immunotherapy in locally advanced NSCLC based on the early report that…
Hagop M. Kantarjian, MD of MD Anderson Cancer Center’s Department of Leukemia gives the trial overview and conclusions of Pfizer’s…
In this presentation from the Treatment Dilemmas in Polycythemia Vera: Leveraging Evidence and Clinical Experience to Improve Patient Care symposium,…
In this presentation from the Treatment Dilemmas in Polycythemia Vera: Leveraging Evidence and Clinical Experience to Improve Patient Care symposium,…
In this presentation from the Treatment Dilemmas in Polycythemia Vera: Leveraging Evidence and Clinical Experience to Improve Patient Care symposium,…
In this discussion, recorded during the 2017 US Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes, held August 4-5, 2017 in…
In this presentation from the 2017 Great Debates & Updates in GI Malignancies, Dr. Tanios S. Bekaii-Saab argues that there…
In this presentation from the 2017 Great Debates & Updates in GI Malignancies, Dr. Ghassan Abou-Alfa argues that regorafenib should…
In this presentation from the 2017 Great Debates & Updates in GI Malignancies, Dr. Mark A, Schattner provides an update…
In this presentation from the 2017 Great Debates & Updates in GI Malignancies, Dr. Eileen O’Reilly provides an update in…
In this presentation from the 2017 Great Debates & Updates in GI Malignancies, Dr. Tanios S. Bekaii-Saab argues that gemcitabine/capecitabine…
In this presentation from the 2017 Great Debates & Updates in GI Malignancies, Dr. Jordan Berlin argues that gemcitabine/nab-paclitaxel is…
In this presentation from the 2017 Great Debates & Updates in GI Malignancies, Dr. Christopher H. Crane argues that preoperative…
In this presentation from the 2017 Great Debates & Updates in GI Malignancies, Dr. Jordan Berlin argues that chemotherapy alone…
In this presentation from the 2017 Great Debates & Updates in GI Malignancies, Dr. Christopher L. Hallemeier argues that surgery…
In this presentation from the 2017 Great Debates & Updates in GI Malignancies, Dr. Christopher H. Crane argues that post-operative…